Wang CS, Wang ST, Lai CT, Lin LJ, Chou P. Impact of influenza vacci- nation on major cause-specific mortality. Vaccine. 2007;25:1196 1203. 870. Johnstone J, Loeb M, Teo KK, Gao P, Dyal L, Liu L,AvezumA, Cardona- Munoz E, Sleight P, Fagard R, Yusuf S; Ongoing Telmisartan Alone and in Combination With Ramipril Global EndPoint Trial (ONTARGET); Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) Investigators. Influenza vaccination and major adverse vascular events in high-risk patients. Circulation. 2012;126:278 286. 871. Davis MM, Taubert K, Benin AL, Brown DW, Mensah GA, Baddour LM, Dunbar S, Krumholz HM; American Heart Association; American College of Cardiology. Influenza vaccination as secondary preven- tion for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology. Circulation. 2006;114:1549 1553. 872. De Berardis G, Lucisano G, D Ettorre A, Pellegrini F, Lepore V, Tognoni G, Nicolucci A. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA. 2012;307:2286 2294. 873. Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple pri- mary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2011;107:1796 1801. 874. Raju N, Sobieraj-Teague M, Hirsh J, O Donnell M, Eikelboom J. Effect of aspirin on mortality in the primary prevention of cardiovascular dis- ease. Am J Med. 2011;124:621 629. 875. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collabora- tive meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849 1860. 876. US Preventive Services Task Force. Aspirin for the prevention of cardio- vascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150:396 404. 877. 